S&P 500
7,667.57
-89.60
-1.16%
Dow
52,746.98
-109.11
-0.21%
Nasdaq
26,148.51
-554.35
-2.08%
NYSE Composite
24,142.18
-110.95
-0.46%
Russell 2000
2,767.87
-13.15
-0.47%
VIX
19.17
+2.49
+14.93%
IBIO · iBio, Inc.
NYSE MKT LLC - Real Time Price • USD
$0.84
+0.00
(+0.39%)
● Market open
DAY'S RANGE
$0.84
$0.84
$0.86
52-WEEK RANGE
$0.84
$0.73
$3.82
What's happening
- IBIO is up 0.39% today, trading at $0.84. — Live quote
- Volume today (6,363) is well below its 3-month average of 830,690. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.07 actual vs. $-0.07 estimated (-7.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IBIO
-56.48%
vs S&P 500
-69.85%
1-YEAR RETURN
IBIO
-24.32%
vs S&P 500
-39.49%
6-MONTH RETURN
IBIO
-59.22%
3-MONTH RETURN
IBIO
-39.13%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q4 2026)
$-0.07
Est. $-0.07
MISS -7.7%
2026-04-26 (Q3 2026)
$-0.06
Est. $-0.06
BEAT +6.1%
2026-01-26 (Q2 2026)
$-0.09
Est. $-0.08
MISS -6.9%
2025-10-26 (Q1 2026)
$-0.11
Est. $-0.10
MISS -5.2%
Valuation Measures & Ratios
Enterprise Value4-$5.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)102.23
Price / Book71.01
EV4 / Revenue-10.56
EV4 / EBITDA—
Profit Margin-3049.40%
Operating Margin-3113.60%
Return on Equity (ROE8)-47.92%
Return on Assets (ROA9)-42.16%
Avg Volume (3M)830,690
Quarterly history (5 periods)
| Measure | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|
| Market cap | $246.1M | $194.8M | $41.7M | $39.8M | $21.4M |
| P/E | -9.01 | -8.14 | -2.20 | -2.43 | -1.08 |
| Price/Sales | — | 649.49 | 138.86 | — | — |
| Price/Book | 3.17 | 3.44 | 0.74 | 3.50 | 1.54 |
| EV/Revenue | — | 553.92 | 45.15 | — | — |
| ROE | -35.21% | -42.32% | -33.79% | -143.98% | -142.04% |
| ROA | -31.81% | -37.17% | -29.51% | -85.78% | -90.96% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,202,419
Change from Prior Settlement-14.88%
% of Float—
Days to Cover (Short Ratio)6.17
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -46.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -3049.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -24.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IBIO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Mar '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $100.0K | $0 | $200.0K | $0 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.4M | -$9.4M | -$6.0M | -$4.9M | -$4.4M | -$4.1M | -$3.6M | -$4.5M |
| Net income | -$7.7M | -$9.0M | -$5.7M | -$4.9M | -$4.4M | -$4.0M | -$3.2M | -$8.2M |
| EPS (diluted) | $-0.06 | $-0.09 | $-0.11 | $-0.49 | $-0.48 | $-0.46 | $-0.85 | $-4.42 |
| EPS (basic) | $-0.06 | $-0.09 | $-0.11 | $-0.49 | $-0.48 | $-0.46 | $-0.85 | $-4.42 |
| Operating margin | — | — | -$6.0K | — | -$2.2K | — | — | — |
| Net margin | — | — | -$5.7K | — | -$2.2K | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $99.1M | $85.8M | $64.4M | $64.2M | $23.2M | $19.1M | $21.7M | $24.5M |
| Total liabilities | $13.4M | $8.3M | $7.8M | $8.1M | $8.3M | $7.7M | $7.8M | $6.8M |
| Stockholders' equity | $85.7M | $77.5M | $56.6M | $56.0M | $14.9M | $11.4M | $13.9M | $17.8M |
| Total current assets | $92.2M | $77.3M | $53.4M | $50.8M | $9.7M | $6.1M | $8.3M | $11.7M |
| Total current liabilities | $11.7M | $6.5M | $5.9M | $6.0M | $6.1M | $5.4M | $4.7M | $3.5M |
| Cash & equivalents | $56.4M | $47.6M | $28.7M | $28.1M | $8.6M | $5.0M | $7.0M | $11.0M |
| Accounts receivable | — | — | — | $65.0K | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $3.1M | $3.3M | $3.4M | $3.2M | $3.2M | $3.3M | $3.4M | $3.5M |
| Intangible assets | $1.8M | $1.8M | $4.3M | $6.8M | $6.8M | $6.1M | $6.1M | $5.4M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $4.4M | $3.0M | $2.7M | $2.8M | $2.2M | $1.5M | $614.0K | $855.0K |
| Accrued liabilities | $5.6M | $1.8M | $1.6M | $850.0K | $1.3M | $1.3M | $1.8M | $1.1M |
| Deferred revenue (current) | $1.1M | $1.1M | $1.1M | $1.1M | $1.2M | $600.0K | $600.0K | $400.0K |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $56.0K | $35.0K | $30.0K | $20.0K | $19.0K | $10.0K | $9.0K | $9.0K |
| Retained earnings | -$365.3M | -$354.7M | -$346.9M | -$337.9M | -$332.2M | -$327.1M | -$322.2M | -$317.8M |
| Accumulated other comprehensive income (loss) | -$45.0K | -$21.0K | $10.0K | -$15.0K | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.2M | -$6.1M | -$5.2M | -$5.7M | -$4.6M | -$3.1M | -$3.9M | -$3.7M |
| Investing cash flow | -$4.4M | -$3.1M | -$3.0M | -$21.5M | $45.0K | -$14.0K | -$2.0K | $713.0K |
| Financing cash flow | $19.4M | $28.2M | $8.8M | $46.7M | $8.2M | $1.1M | -$152.0K | -$162.0K |
| Free cash flow | -$6.2M | -$6.1M | -$5.8M | -$5.7M | -$4.6M | -$3.1M | -$3.9M | -$3.7M |
| Capital expenditures | $19.0K | $11.0K | $516.0K | $32.0K | $1.0K | $14.0K | $1.0K | $0 |
| Share-based compensation | $420.0K | $377.0K | $253.0K | $323.0K | $270.0K | $370.0K | $475.0K | $415.0K |
| Deferred income taxes | -$6.4M | — | — | — | -$8.5M | — | — | — |
| Change in accounts receivable | $0 | $0 | $0 | $65.0K | — | $0 | $0 | $0 |
| Change in accounts payable | $1.4M | $380.0K | -$29.0K | $495.0K | $712.0K | $863.0K | -$241.0K | $497.0K |
| Purchases of investments | $9.9M | $8.5M | $2.5M | $21.5M | — | $0 | $0 | $0 |
| Sales/maturities of investments | $5.4M | $5.4M | — | — | — | $0 | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | $50.0M | $6.2M | — | — | $0 |
Income statement
| Line item | Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 |
|---|---|---|---|---|---|
| Revenue | $100.0K | $400.0K | $225.0K | $0 | — |
| Gross profit | — | — | — | — | $2.2M |
| Operating income | -$35.1M | -$18.6M | -$16.6M | -$29.3M | -$29.7M |
| Net income | -$33.0M | -$18.4M | -$24.9M | -$65.0M | -$50.3M |
| EPS (diluted) | $-0.32 | $-1.75 | $-6.50 | $-106.19 | $-5.78 |
| EPS (basic) | $-0.32 | $-1.75 | $-6.50 | $-106.19 | $-5.78 |
| Operating margin | -$35.1K | -$4.7K | -$7.4K | — | — |
| Net margin | -$33.0K | -$4.6K | -$11.1K | — | — |
Balance sheet
| Line item | Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 |
|---|---|---|---|---|---|
| Total assets | $99.1M | $23.2M | $28.7M | $41.2M | $99.4M |
| Total liabilities | $13.4M | $8.3M | $7.4M | $25.8M | $35.9M |
| Stockholders' equity | $85.7M | $14.9M | $21.3M | $15.4M | $63.5M |
| Total current assets | $92.2M | $9.7M | $15.7M | $26.3M | $45.1M |
| Total current liabilities | $11.7M | $6.1M | $3.8M | $22.1M | $30.4M |
| Cash & equivalents | $56.4M | $8.6M | $14.2M | $4.3M | $22.7M |
| Accounts receivable | — | — | $0 | $0 | $1.0M |
| Inventory | — | — | $0 | $0 | $3.9M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $3.1M | $3.2M | $3.6M | $4.2M | $1.4M |
| Intangible assets | $1.8M | $6.8M | $5.4M | $5.4M | $4.9M |
| Accounts payable | $4.4M | $2.2M | $358.0K | $1.8M | $4.3M |
| Accrued liabilities | $5.6M | $1.3M | $2.0M | $4.6M | $3.8M |
| Deferred revenue (current) | $1.1M | $1.2M | $200.0K | $0 | $100.0K |
| Other current liabilities | — | — | — | $1.9M | — |
| Common stock & paid-in capital | $56.0K | $19.0K | $9.0K | $1.0K | $9.0K |
| Retained earnings | -$365.3M | -$332.2M | -$313.8M | -$288.9M | -$223.9M |
| Accumulated other comprehensive income (loss) | -$45.0K | — | — | — | -$213.0K |
Cash flow
| Line item | Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.2M | -$15.3M | -$18.6M | -$30.4M | -$37.5M |
| Investing cash flow | -$32.0M | $742.0K | $906.0K | $7.0M | -$5.1M |
| Financing cash flow | $103.0M | $8.9M | $24.5M | $2.3M | -$6.1M |
| Free cash flow | -$23.8M | -$15.3M | -$18.8M | -$36.2M | -$44.8M |
| Capital expenditures | $578.0K | $16.0K | $210.0K | $5.7M | $7.3M |
| Share-based compensation | $1.4M | $1.5M | $2.0M | $4.4M | $4.4M |
| Deferred income taxes | -$6.4M | -$8.5M | -$5.3M | -$12.8M | — |
| Change in accounts receivable | $65.0K | — | — | -$1.0M | $886.0K |
| Change in accounts payable | $2.2M | $1.8M | -$1.5M | -$625.0K | $1.2M |
| Purchases of investments | $42.3M | — | — | $6.8M | $5.4M |
| Sales/maturities of investments | $10.8M | — | — | $4.1M | $13.6M |
| Other financing activities | — | $6.2M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IBIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers33.0%
Shares Outstanding104,060,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 4,007,881 | $7.0M | 3.85% | +29.0% | 2026-08-13 |
| Cormorant Asset Management, LP | 3,570,000 | $6.2M | 3.43% | +0.0% | 2026-08-14 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3,520,490 | $6.2M | 3.38% | +1457.7% | 2026-08-07 |
| Vestal Point Capital, LP | 2,600,000 | $4.5M | 2.50% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,098,151 | $3.7M | 2.02% | +92.8% | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 1,953,467 | $3.4M | 1.88% | +0.0% | 2026-08-14 |
| Ensign Peak Advisors, Inc | 1,832,457 | $3.2M | 1.76% | +0.0% | 2026-08-14 |
| Woodline Partners LP | 1,776,547 | $3.1M | 1.71% | +0.0% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 1,651,473 | $2.9M | 1.59% | +6.6% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,384,029 | $2.4M | 1.33% | +44.7% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 1,170,893 | $2.0M | 1.13% | +15.8% | 2026-08-13 |
| Bank Of America Corp /De/ | 1,121,492 | $2.0M | 1.08% | +286.2% | 2026-08-14 |
| Ikarian Capital, LLC | 957,062 | $1.7M | 0.92% | +0.0% | 2026-08-14 |
| Sio Capital Management, LLC | 904,268 | $1.6M | 0.87% | +0.0% | 2026-07-15 |
| MARSHALL WACE, LLP | 904,132 | $1.6M | 0.87% | +45.7% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 500,816 | $876.6K | 0.48% | +29.2% | 2026-08-12 |
| Walleye Capital LLC | 500,375 | $875.7K | 0.48% | +28.8% | 2026-07-30 |
| Squarepoint Ops LLC | 498,872 | $873.0K | 0.48% | +0.0% | 2026-08-14 |
| NOESIS CAPITAL MANGEMENT CORP | 405,000 | $708.8K | 0.39% | +30.0% | 2026-08-04 |
| TWO SIGMA INVESTMENTS, LP | 400,667 | $701.2K | 0.39% | -2.0% | 2026-08-07 |
| Ally Bridge Group (NY) LLC | 390,147 | $682.8K | 0.37% | +0.0% | 2026-08-14 |
| ADAR1 Capital Management, LLC | 375,531 | $657.2K | 0.36% | -20.1% | 2026-08-14 |
| Verdad Advisers, LP | 298,927 | $523.1K | 0.29% | +430.8% | 2026-08-14 |
| VANGUARD FIDUCIARY TRUST CO | 286,875 | $502.0K | 0.28% | +39.9% | 2026-06-30 |
| BOOTHBAY FUND MANAGEMENT, LLC | 254,412 | $445.2K | 0.24% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-19 to 2026-03-26
Recent transactions
- Most recent: Banjak Marc (Chief Legal Officer) — Open market purchase of 12,500 shares on 2026-03-26.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Banjak Marc | Chief Legal Officer | Open market purchase | 2026-03-26 | 12,500 |
| Duran Felipe | Chief Financial Officer | Open market purchase | 2026-03-19 | 24,835 |
| Brenner Martin | See Remarks | Open market purchase | 2026-03-19 | 12,336 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-26 | Banjak Marc | Chief Legal Officer | Open market purchase | 12,500 | $1.64 |
| 2026-03-26 | Banjak Marc | Chief Legal Officer | Open market purchase | 1,434 | $1.76 |
| 2026-03-19 | Duran Felipe | Chief Financial Officer | Open market purchase | 24,835 | $2.02 |
| 2026-03-19 | Brenner Martin | See Remarks | Open market purchase | 12,336 | $2.02 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 15:21 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-15 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-13 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-28 | 10-K | 2026-06-30 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
Recent news
Headlines about IBIO (iBio, Inc.). Links open the publisher — we don’t host full articles.
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2026-10-20 -
IBIO 8-K & SEC Filings
Yahoo Finance · 2026-10-19 -
Form 4 Ibio Inc: David Arkowitz (Director) For: 14 October By Investing.com
Investing.com Nigeria · 2026-10-16 -
At $0.78 per share, 38,000 options go to iBio (IBIO) director Elizabeth Stoner.
Stock Titan · 2026-10-15 -
38,000 options granted to iBio (IBIO) director Alexandra Kropotova vest monthly over 12 months.
Stock Titan · 2026-10-15 -
A director receives 38,000 iBio (IBIO) stock options with a $0.78 exercise price.
Stock Titan · 2026-10-15 -
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
Yahoo · 2026-10-13 -
iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity
Benzinga · 2026-10-13
No headlines in this category right now — try “All”.